{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:09:20Z","timestamp":1788887360820,"version":"build-2803163510"},"reference-count":49,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>The natural history of pancreatic neuroendocrine tumors (NETs) can span decades of slow progression, but it is unpredictable, with a more aggressive course also being common. The two clinical biomarkers currently used to define the grade of a tumor, the Ki67 index and the mitotic index, are not able to fully capture the course of individual patients. This creates an unmet need to discover better prognostic biomarkers to inform therapeutic decisions, as well as therapies with overall survival benefit. Two genomic series of pancreatic NETs were examined to discover sub-sets with divergent characteristics. Primary data were downloaded from the cBioportal cancer genomics portal and analyzed at the individual sample level. Pancreatic NET patients without MEN1\/DAXX\/ATRX mutations were younger than NET patients with any of these mutations. Pancreatic NETs had consistently low tumor mutation burden but were heterogeneous in their Fraction Genome Altered (FGA), a metric of chromosomal instability (CIN), with one group presenting high FGA and another possessing low to intermediate FGA. FGA did not correlate with Ki67, but high FGA was most prevalent in cases with mutations in MEN1 and DAXX or ATRX. TSC2 mutations were significantly more prevalent in the group with high FGA.<\/jats:p>","DOI":"10.3390\/ijms27188002","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:46:04Z","timestamp":1788885964000},"page":"8002","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Genomic Patterns of Well-Differentiated Pancreatic Neuroendocrine Tumors (NETs) Identify Sub-Sets for Rational Therapeutic Targeting"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9301-5951","authenticated-orcid":false,"given":"Ioannis A.","family":"Voutsadakis","sequence":"first","affiliation":[{"name":"Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA"},{"name":"Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA"},{"name":"Section of Internal Medicine, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, ON P3E 2C6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.5114\/aoms.2020.94845","article-title":"The global burden of pancreatic cancer","volume":"16","author":"Lippi","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2515798","DOI":"10.1001\/jamanetworkopen.2025.15798","article-title":"Epidemiology of Neuroendocrine Neoplasms in the US","volume":"8","author":"Dasari","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102659","DOI":"10.1016\/j.canep.2024.102659","article-title":"Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009\u20132021","volume":"93","author":"Stang","year":"2024","journal-title":"Cancer Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e36094","DOI":"10.1097\/MD.0000000000036094","article-title":"A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment","volume":"102","author":"Alshareefy","year":"2023","journal-title":"Medicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.3748\/wjg.v21.i32.9512","article-title":"Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management","volume":"21","author":"Cloyd","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bevere, M., Gkountakos, A., Martelli, F.M., Scarpa, A., Luchini, C., and Simbolo, M. (2023). An Insight on Functioning Pancreatic Neuroendocrine Neoplasms. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020303"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-025-04296-y","article-title":"Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping","volume":"488","author":"Kasajima","year":"2026","journal-title":"Virchows Arch."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1245\/s10434-024-15632-y","article-title":"Subgrading of G2 Pancreatic Neuroendocrine Tumors as 2A (Ki67 3% to < 10%) Versus 2B (10% to \u2264 20%) Identifies Behaviorally Distinct Subsets in Keeping with the Evolving Management Protocols","volume":"31","author":"Eren","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12022-025-09866-z","article-title":"Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: An Analysis of 904 Patients with 7882 Person-Years of Follow-Up","volume":"36","author":"Kiemen","year":"2025","journal-title":"Endocr. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12943-026-02697-4","article-title":"Multi-omic profiles of neuroendocrine neoplasms of the pancreas: An integrated landscape","volume":"25","author":"Bevere","year":"2026","journal-title":"Mol. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","article-title":"PIK3CA\/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors","volume":"18","author":"Akcakanat","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e008248","DOI":"10.1136\/bmjopen-2015-008248","article-title":"Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: Protocol for a phase II clinical trial","volume":"5","author":"Neychev","year":"2015","journal-title":"BMJ Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10732748261432278","DOI":"10.1177\/10732748261432278","article-title":"Integrative Molecular Analysis to Predict Clinical Benefit of Everolimus in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs)","volume":"33","author":"Han","year":"2026","journal-title":"Cancer Control"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1530\/ERC-16-0329","article-title":"mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors","volume":"23","author":"Falletta","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/10781552211073673","article-title":"Biomarkers of everolimus efficacy in breast cancer therapy","volume":"28","author":"Voutsadakis","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12032-018-1112-9","article-title":"Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer","volume":"35","author":"Okazaki","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1158\/1078-0432.CCR-20-4548","article-title":"Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations","volume":"27","author":"Adib","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.21037\/jtd-21-195","article-title":"A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations","volume":"13","author":"Devarakonda","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.humpath.2024.06.015","article-title":"Loss of ATRX and DAXX in pancreatic neuroendocrine tumors: Association with recurrence risk, cellular phenotype, and heterogeneity","volume":"150","author":"Yasunaga","year":"2024","journal-title":"Hum. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Clatterbuck Soper, S.F., and Meltzer, P.S. (2023). ATRX\/DAXX: Guarding the Genome against the Hazards of ALT. Genes, 14.","DOI":"10.3390\/genes14040790"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41467-019-13824-9","article-title":"Genomic footprints of activated telomere maintenance mechanisms in cancer","volume":"11","author":"Sieverling","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.molcel.2018.05.014","article-title":"ATRX Promotes DNA Repair Synthesis and Sister Chromatid Exchange during Homologous Recombination","volume":"71","author":"Elbakry","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12664-024-01678-z","article-title":"Prognostic and predictive significance of p53 and ATRX in neuroendocrine neoplasms of GIT and pancreas and their utility as an adjunct to accurate diagnosis-An eight-year retrospective study","volume":"44","author":"Ail","year":"2025","journal-title":"Indian. J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7951","DOI":"10.1093\/nar\/gkad548","article-title":"MEN1 is a regulator of alternative splicing and prevents R-loop-induced genome instability through suppression of RNA polymerase II elongation","volume":"51","author":"Jin","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/carcin\/bgae024","article-title":"CRL4DCAF4 E3 ligase-mediated degradation of MEN1 transcriptionally reactivates hTERT to sustain immortalization in colorectal cancer cells","volume":"45","author":"Ao","year":"2024","journal-title":"Carcinogenesis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1210\/en.2019-00274","article-title":"Menin Associates with the Mitotic Spindle and Is Important for Cell Division","volume":"160","author":"Sawicki","year":"2019","journal-title":"Endocrinology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10577-023-09741-9","article-title":"Permission to pass: On the role of p53 as a gatekeeper for aneuploidy","volume":"31","author":"Marques","year":"2023","journal-title":"Chromosome Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"a041701","DOI":"10.1101\/cshperspect.a041701","article-title":"Telomere Dynamics in Human Health and Disease","volume":"17","author":"Baird","year":"2025","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1038\/s41467-018-06498-2","article-title":"ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup","volume":"9","author":"Chan","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41525-018-0058-3","article-title":"Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer","volume":"3","author":"Lawrence","year":"2018","journal-title":"NPJ Genom. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/PAS.0000000000001860","article-title":"Recurrent Loss of Heterozygosity in Pancreatic Neuroendocrine Tumors","volume":"46","author":"Parilla","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"a026468","DOI":"10.1101\/cshperspect.a026468","article-title":"SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation","volume":"7","author":"Fahey","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"168796","DOI":"10.1016\/j.jmb.2024.168796","article-title":"Context-Dependent and Locus-Specific Role of H3K36 Methylation in Transcriptional Regulation","volume":"437","author":"Lee","year":"2025","journal-title":"J. Mol. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8897","DOI":"10.1074\/jbc.M212134200","article-title":"The Set2 histone methyltransferase functions through the phosphorylated carboxyl-terminal domain of RNA polymerase II","volume":"278","author":"Li","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2013). Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 499, 43\u201349.","DOI":"10.1038\/nature12222"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., and Shen, R. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373. Erratum in Nature 2013, 500, 242.","DOI":"10.1038\/nature12325"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","article-title":"Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation","volume":"28","author":"Pfister","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.tips.2025.09.005","article-title":"WEE-family kinases in cancer: Synthetic lethal interactions and drug discovery","volume":"47","author":"Wang","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"105394","DOI":"10.1016\/j.critrevonc.2026.105394","article-title":"Role of O6-methylguanine DNA methyltransferase status as predictive factor for alkylatin-based chemotherapy in advanced neuroendocrine tumors: State of the art","volume":"225","author":"Maratta","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.6004\/jnccn.2025.7035","article-title":"Whole-Exome Sequencing Reveals High Prevalence of Germline Alterations in Neuroendocrine Neoplasms","volume":"23","author":"Sukrithan","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17588359251356335","DOI":"10.1177\/17588359251356335","article-title":"Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: A multinational study","volume":"17","author":"Riechelmann","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00267","article-title":"Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability","volume":"2","author":"Raj","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8002\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:46:46Z","timestamp":1788886006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":49,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188002"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188002","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}